Risk Factors for Progression from Cytomegalovirus Viremia to Cytomegalovirus Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 6, 2012, Pages 881-886

  Jang, Ji Eun ^a   Hyun, Shin Young ^a   Kim, Yun Deok ^a   Yoon, Sul Hee ^a   Hwang, Doh Yu ^a   Kim, Soo Jeong ^a   Kim, Yuri ^a   Kim, Jin Seok ^a   Cheong, June Won ^a   Min, Yoo Hong ^a  

^a Yonsei University   (South Korea)

Author keywords

Allo HSCT; CMV disease; Leukopenia; Prediction

Indexed keywords

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; FEMALE; HAZARD RATIO; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUTROPENIA; RISK FACTOR; VIRAL CLEARANCE; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NEUTROPENIA; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIREMIA;

EID: 84860839178     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.037     Document Type: Article

References (23)

1. Boeckh M., Nichols W.G., Papanicolaou G., et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003, 9:543-558.
2. Stocchi R., Ward K.N., Fanin R., et al. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Haematologica 1999, 84:71-79.
3. Boeckh M., Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113:5711-5719.
4. Ozdemir E., Saliba R.M., Champlin R.E., et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007, 40:125-136.
5. Buyck H.C., Prentice H.G., Griffiths P.D., et al. The risk of early and late CMV DNAemia associated with Campath use in stem cell transplant recipients. Bone Marrow Transplant 2010, 45:1212-1219.
6. George B., Pati N., Gilroy N., et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 2010, 12:322-329.
7. Cantoni N., Hirsch H.H., Khanna N., et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant 2010, 16:1309-1314.
8. Enright H., Haake R., Weisdorf D., et al. Cytomegalovirus pneumonia after bone marrow transplantation: risk factors and response to therapy. Transplantation 1993, 55:1339-1346.
9. Ljungman P., Engelhard D., Link H., et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of the European Bone Marrow Transplant Group. Clin Infect Dis 1992, 14:831-835.
10. van der Meer J.T., Drew W.L., Bowden R.A., et al. Summary of the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis and Cytomegalovirus Infection. Antiviral Res 1996, 32:119-140.
11. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
12. Reusser P., Riddell S.R., Meyers J.D., et al. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991, 78:1373-1380.
13. Hakki M., Riddell S.R., Storek J., et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003, 102:3060-3067.
14. Li C.R., Greenberg P.D., Gilbert M.J., et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994, 83:1971-1979.
15. Piñana J.L., Martino R., Barba P., et al. Cytomegalovirus infection and disease after reduced-intensity conditioning allogeneic stem cell transplantation: single-centre experience. Bone Marrow Transplant 2010, 45:534-542.
16. Barron M.A., Gao D., Springer K.L., et al. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients. Clin Infect Dis 2009, 49:1777-1783.
17. Dodero A., Carrabba M., Milani R., et al. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol 2005, 33:920-927.
18. Peres R.M., Costa C.R., Andrade P.D., et al. Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR. BMC Infect Dis 2010, 10:147.
19. Ikewaki J., Ohtsuka E., Satou T., et al. Real-time PCR assays based on distinct genomic regions for cytomegalovirus reactivation following hematopoietic stem cell transplantation. Bone Marrow Transplant 2005, 35:403-410.
20. Emery V.C., Sabin C.A., Cope A.V., et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000, 355:2032-2036.
21. Meyers J.D., Ljungman P., Fisher L.D. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990, 162:373-380.
22. Bodey G.P., Buckley M., Sathe Y.S., et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966, 64:328-340.
23. Sia I.G., Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000, 13:83-121.